All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Performance comparison

Mecasermin (Increlex) vs Tesamorelin

An educational, source-based comparison of Mecasermin (Increlex) and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.

IGF-1 · Endocrine
Mecasermin (Increlex)

Recombinant human IGF-1 for severe primary IGF-1 deficiency.

Mechanism

Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.

Research areas
  • Severe primary IGF-1 deficiency
  • Growth failure with GH gene deletion and neutralizing GH antibodies
Considerations
  • FDA-approved.
  • Hypoglycemia — must be taken with food.
  • Tonsillar hypertrophy, intracranial hypertension reported.
Full Mecasermin (Increlex) profile →
Growth Hormone Axis
Tesamorelin

GHRH analog FDA-approved for HIV-associated visceral fat.

Mechanism

A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.

Research areas
  • Visceral adipose tissue reduction (approved)
  • Cognitive function in older adults (research)
  • NAFLD / hepatic fat (research)
Considerations
  • FDA-approved only for HIV-associated lipodystrophy.
  • May affect glucose tolerance; monitor in at-risk patients.
  • Requires physician oversight.
Full Tesamorelin profile →

Mecasermin (Increlex) vs Tesamorelin — Key differences

  • Class: Mecasermin (Increlex) is classified as IGF-1 · Endocrine, while Tesamorelin is Growth Hormone Axis.
  • Primary research focus: Mecasermin (Increlex)severe primary igf-1 deficiency; Tesamorelinvisceral adipose tissue reduction (approved).
  • Tag: FDA-Approved · Endocrine vs Body composition.

Related comparisons